Get the Stockscreener App
1,166.51
1.36%
-16.11
After Hours:
1166.59
0.08
+0.01%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,166.51, with a volume of 1.84M.
It is down -1.36% in the last 24 hours and up +4.55% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,182.62
Open:
$1190.7
24h Volume:
1.84M
Relative Volume:
0.85
Market Cap:
$1.04T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.99
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+0.78%
1M Performance:
+4.55%
6M Performance:
+25.49%
1Y Performance:
+42.36%
1-Day Range:
$1,158.40
$1,193.30
1-Week Range:
$1,131.21
$1,206.63
52-Week Range:
$783.85
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,166.51 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.61 | 599.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
274.36 | 484.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.98 | 350.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.41 | 270.68B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Upgrade | Berenberg | Hold → Buy |
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades (XLV:NYSEARCA) - Seeking Alpha
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades - TradingView
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? - Zacks Investment Research
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Lilly seeks to provide $19.3M to Lebanon for expanded hazmat services - Inside INdiana Business
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Eli Lilly presented new trial data. Eli Lilly stock gains 1.09 percent - ad-hoc-news.de
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next. - The Motley Fool
Eli Lilly says combining Taltz and Zepbound works better than Taltz alone in psoriasis study - MedWatch
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Eli Lilly Sued Over Alleged Digestive Complications From GLP-1 Medication - InkFreeNews.com
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO - Bloomberg.com
Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales - Law360
Eli Lilly Says Weight Clinic 'Mocks' FDA With Illegal Drugs - Law360
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Yahoo Finance
3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity - Inside INdiana Business
Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell - Zacks Investment Research
Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell - Zacks Investment Research
Eli Lilly and Co. stock trades at EUR 1031.20, market cap USD 1,088.7 billion - AD HOC NEWS
Eli Lilly, Glaukos among market cap stock movers on Thursday - Investing.com
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity - The Indiana Lawyer
Eli Lilly Quietly Expands Its Alzheimer’s Pipeline With New Early-Stage Trial - TipRanks
Transcript: Eli Lilly Q2 2026 Earnings Conference Call - Benzinga
Eli Lilly and Co Stock (LLY) Moved Down by 3.09% on Oct 8: Facts Behind the Movement - TradingKey
Eli Lilly Sues More Vendors Selling ‘Illicit’ Weight Loss Drugs - Bloomberg Law News
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now - Zacks Investment Research
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - TradingView
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
PhRMA Sues Trump Administration Over Medicare Drug Pricing RuleEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly (LLY) shareholder Lilly Endowment proposes another sale after $386M in August proceeds. - Stock Titan
General Medicine banks $120M backed by a16z, Eli Lilly and Mercy Health to build out healthcare storefront - Fierce Healthcare
Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement - TradingKey
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jonsson Patrik | EVP & President, LLY Int'l |
Aug 17 '26 |
Sale |
1,175.10 |
6,500 |
7,638,150 |
54,147 |
| Patrik Jonsson | Officer |
Aug 17 '26 |
Proposed Sale |
1,175.10 |
6,500 |
7,638,150 |
0 |
| Zakrowski Donald A | SVP, Finance, & CAO |
Aug 10 '26 |
Sale |
1,185.01 |
2,000 |
2,370,020 |
1,526 |
| DONALD ZAKROWSKI | Officer |
Aug 10 '26 |
Proposed Sale |
1,185.71 |
2,000 |
2,371,420 |
0 |
| Hakim Anat | Officer |
Aug 07 '26 |
Proposed Sale |
1,190.00 |
10,000 |
11,900,000 |
0 |
| Hakim Anat | EVP, GC & Secretary |
Aug 07 '26 |
Sale |
1,190.00 |
5,000 |
5,950,000 |
11,875 |
| Seymour Melissa | EVP, Global Quality |
Aug 01 '26 |
Option Exercise |
0.00 |
981 |
0 |
1,506 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jul 07 '26 |
Proposed Sale |
1,200.06 |
310,000 |
372,018,600 |
0 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jun 26 '26 |
Proposed Sale |
1,127.69 |
305,000 |
343,945,450 |
0 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Jun 10 '26 |
Sale |
1,150.77 |
2,500 |
2,876,925 |
29,804 |
5.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):